Inhibitory effects of rHP-NAP IgY against Helicobacter pylori attachment to AGS cell line.
Helicobacter pylori is a major human pathogen related to gastric adenocarcinoma and gastroduodenal diseases. Treatment of H. pylori infections is complicated by the rise of antibiotic resistance, necessitating investigation of alternative therapies. One such alternative is passive immunization by oral administration of antibacterial immunoglobulin. In the present study, chicken immunoglobulin (IgY) was used for passive immunotherapy against a major virulence factor of H. pylori, namely recombinant HP-Nap protein. Recombinant HP-Nap was prepared and used to immunize hens. IgY was purified from the eggs by polyethylene glycol precipitation method with a total IgY-HP-NAP yield of 30 mg per egg. The inhibitory effect of specific IgY on H. pylori attachment was investigated in AGS cell line infected by the bacteria. The results demonstrate the potent effect of IgY- HP-NAP in inhibition of H. pylori attachment to the AGS cells.
Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Katayoun
K
Borhani
Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Electronic address: mmmobarez@modares.ac.ir.
Ashraf
A
Mohabati Mobarez
Diagnosis Biotechnology Unit, Pasteur Institute of Iran, Alborz, Iran. Electronic address: khabiri@pasteur.ac.ir.
Ali Reza
AR
Khabiri
Department of Genetic, Faculty of Life Sciences, Tarbiat Modares University, Tehran, Iran.
Mehrdad
M
Behmanesh
Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Nima
N
Khoramabadi
D000818:Animals; D001422:Bacterial Adhesion / Q000187:drug effects*; D045744:Cell Line, Tumor; D002645:Chickens; D004847:Epithelial Cells / Q000382:microbiology*; D016480:Helicobacter pylori / Q000187:drug effects* / Q000276:immunology*; D006801:Humans; D007136:Immunoglobulins / Q000302:isolation & purification / Q000378:metabolism*; D007155:Immunologic Factors / Q000302:isolation & purification / Q000378:metabolism*; D013134:Spiperone / Q000031:analogs & derivatives; D037521:Virulence Factors / Q000037:antagonists & inhibitors* / Q000276:immunology
C016512:IgY; D007136:Immunoglobulins; D007155:Immunologic Factors; D037521:Virulence Factors; D013134:Spiperone; C043186:N-(4-aminophenethyl)spiroperidol
Alternative therapy; Gastrointestinal disease; HP-NAP; IgY; Immunotherapy